Geron Corp Files 8-K, Confirms Corporate Details & Nasdaq Listing
Ticker: GERN · Form: 8-K · Filed: Jan 30, 2024 · CIK: 886744
| Field | Detail |
|---|---|
| Company | Geron Corp (GERN) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, administrative, filing-update
TL;DR
**Geron filed a routine 8-K, just confirming their name and Nasdaq listing.**
AI Summary
Geron Corporation filed an 8-K on January 30, 2024, to update its corporate information, specifically confirming its exact name as "GERON CORPORATION" and its trading symbol as GERN on The Nasdaq Stock Market LLC. This filing is a routine administrative update, indicating no new material events but rather a reaffirmation of existing corporate details. For investors, this matters because it confirms the company's current legal and trading status, ensuring transparency and accurate identification for stock transactions.
Why It Matters
This filing is a standard administrative update, confirming Geron Corporation's legal name and its listing on Nasdaq under GERN. It provides clarity and ensures accurate identification for investors and regulatory bodies.
Risk Assessment
Risk Level: low — This 8-K is purely administrative and does not disclose any new material events or changes that would impact the company's operations or financial standing.
Analyst Insight
A smart investor would note this as a routine administrative filing that provides no new material information to act upon. It simply confirms existing corporate details, so no immediate action is warranted based on this specific 8-K.
Key Numbers
- 000-20859 — Commission File Number (identifies Geron's filings with the SEC)
- 75-2287752 — IRS Employer Identification No. (identifies Geron for tax purposes)
Key Players & Entities
- GERON CORPORATION (company) — the exact name of the registrant
- Geron Corp (company) — the company filing the 8-K
- Nasdaq Stock Market LLC (company) — the exchange where Geron's stock is registered
- GERN (company) — the trading symbol for Geron's Common Stock
- January 30, 2024 (date) — the date of the earliest event reported and filing date
- Delaware (company) — state of incorporation for Geron Corporation
- 000-20859 (dollar_amount) — Commission File Number
- 75-2287752 (dollar_amount) — IRS Employer Identification No.
- 919 E. HILLSDALE BLVD., SUITE 250 FOSTER CITY, CALIFORNIA 94404 (company) — address of principal executive offices
- 650-473-7700 (dollar_amount) — Registrant's telephone number
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is "GERON CORPORATION".
On which stock exchange is Geron Corporation's Common Stock registered?
Geron Corporation's Common Stock, with a $0.001 par value, is registered on The Nasdaq Stock Market LLC.
What is the trading symbol for Geron Corporation's Common Stock?
The trading symbol for Geron Corporation's Common Stock is GERN.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 30, 2024.
What is Geron Corporation's state or other jurisdiction of incorporation?
Geron Corporation's state of incorporation is Delaware.
Filing Stats: 941 words · 4 min read · ~3 pages · Grade level 16 · Accepted 2024-01-30 08:00:12
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value GERN The Nasdaq Stock Mar
Filing Documents
- gern-20240130.htm (8-K) — 42KB
- 0000950170-24-008536.txt ( ) — 157KB
- gern-20240130.xsd (EX-101.SCH) — 27KB
- gern-20240130_htm.xml (XML) — 5KB
01
Item 8.01 Other Events. As previously disclosed, in August 2023, Geron Corporation ("Geron" or the "Company") announced that its New Drug Application ("NDA") for the use of imetelstat for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents, was accepted by the United States Food and Drug Administration ("FDA") for review and assigned a Prescription Drug User Fee Act ("PDUFA") action date of June 16, 2024. On January 30, 2024, the FDA provided notice in the Federal Register that it has scheduled an advisory committee meeting of the Oncologic Drugs Advisory Committee as part of the NDA review, to be held virtually on March 14, 2024, from 9:30 a.m. to 3:00 p.m. Eastern Time. The meeting will be open to the public. For additional information, please see https://federalregister.gov/d/2024-01797 . Use of Forward-Looking Statements Except for the historical information contained herein, this Current Report on Form 8-K contains forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, including, without limitation, those regarding the PDUFA action date for Geron's imetelstat NDA and the date of the scheduled FDA advisory committee meeting, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: uncertainty of regulatory actions, approvals or clearances, including the risks that the PDUFA action date for the NDA may be extended and that the FDA may ultimately determine not to approve the NDA in its present form or at all; that the date for